Drugging the ‘undruggable’ cancer targets

Cited by (949)

Items 501–600 of 949

1. Multi-task learning for predicting synergistic drug combinations based on auto-encoding multi-relational graphs
   Wenyu Shan, Cong Shen, Lingyun Luo, Pingjian Ding · 2023 · iScience
2. RASON promotes KRASG12C-driven tumor progression and immune evasion in non-small cell lung cancer
   Jianzhuang Wu, Kexin Xie, Yixuan Zhang, Weiyi Zhang, Rongjie Cheng, Yaliang Zhang, Yugui Xia, Tongyan Liu, Rong H. Yin, Yudong Qiu et al. · 2025 · Journal of Experimental & Clinical Cancer Research
3. High-Throughput Screening and Triage Assays Identify Small Molecules Targeting c-MYC in Cancer Cells
   Lorena A. Kallal, Anna Waszkiewicz, Jon‐Paul Jaworski, Anthony Della Pietra, Tom Berrodin, Pat G. Brady, Anthony J. Jurewicz, Xin Zeng, Lisa A. Payne, Jesús R. Medina et al. · 2021 · SLAS DISCOVERY
4. CS2164 and Venetoclax Show Synergistic Antitumoral Activities in High Grade B-Cell Lymphomas With MYC and BCL2 Rearrangements
   Delin Yuan, Genhong Li, Lian Yu, Yuelong Jiang, Yuanfei Shi, Qiulin Chen, Xiaomei Ma, Lan V. Pham, Ken H. Young, Manman Deng et al. · 2021 · Frontiers in Oncology
5. Dual Inhibition of Myc Transcription and PI3K Activity Effectively Targets Colorectal Cancer Stem Cells
   Miriam Gaggianesi, Laura Rosa Mangiapane, Chiara Modica, Vincenzo Davide Pantina, Gaetana Porcelli, Simone Di Franco, Melania Lo Iacono, Caterina D’Accardo, Francesco Verona, Irene Pillitteri et al. · 2022 · Cancers
6. Identification of Trovafloxacin, Ozanimod, and Ozenoxacin as Potent c‐Myc G‐Quadruplex Stabilizers to Suppress c‐Myc Transcription and Myeloma Growth
   Jinyuan Zhang, Tao Wang, Xiaoju Geng, Linlin Liu, Jian Gao · 2022 · Molecular Informatics
7. Targeting General Transcriptional Machinery as a Therapeutic Strategy for Adult T-Cell Leukemia
   Regina Wan Ju Wong, Takashi Ishida, Takaomi Sanda · 2018 · Molecules
8. Design, synthesis, and in vitro evaluation of N-(3-(3-alkyl-1H-pyrazol-5-yl) phenyl)-aryl amide for selective RAF inhibition
   Hoyong Jung, Jinwoong Kim, Daseul Im, Hyungwoo Moon, Jung‐Mi Hah · 2019 · Bioorganic & Medicinal Chemistry Letters
9. Smart Nanocarriers for Targeted Cancer Therapy
   Chiara Martinelli · 2020 · Anti-Cancer Agents in Medicinal Chemistry
10. An approach for the intracellular delivery of IgG via enzymatic ligation with a cell-permeable attenuated cationic amphiphilic lytic peptide
    Yoshimasa Kawaguchi, Sakahiro Terada, Shiroh Futaki · 2024 · Bioorganic & Medicinal Chemistry
11. Structure‐Based Design of Bicyclic Helical Peptides That Target the Oncogene β‐Catenin
    Alejandro Yeste‐Vázquez, Felix M. Paulussen, Mathias Wendt, Rasmus Klintrot, Clemens Schulte, Kerstin Wallraven, Lieke van Gijzel, Boris Simeonov, Maurice van der Gaag, Alan Gerber et al. · 2024 · Angewandte Chemie International Edition
12. In silico assessments of the small molecular boron agents to pave the way for artificial intelligence-based boron neutron capture therapy
    Ying‐Jun Zhang, Jianghong Cai, Narayan S. Hosmane, Yinghuai Zhu · 2024 · European Journal of Medicinal Chemistry
13. Perspectives on Applications of 19F-NMR in Fragment-Based Drug Discovery
    Qingxin Li, CongBao Kang · 2024 · Molecules
14. hnRNPL phase separation activates PIK3CB transcription and promotes glycolysis in ovarian cancer
    Fengjiang Qin, Yuya Wang, Chenyue Yang, Yifei Ren, Qinglv Wei, Yan Tang, Jie Xu, Haocheng Wang, Fatao Luo, Qingya Luo et al. · 2025 · Nature Communications
15. In situ construction of intracellular supramolecular assemblies as an alternative strategy for protein degradation
    Xiaoqian Hu, Qingxin Yao, Xiaobo Wu, Jiali Chen, Ruijia Zhang, Yan Zhao, Yuan Gao · 2025 · Nature Communications
16. DNA-based nanostructures for cell membrane receptor regulation and disease treatment
    Zhongyu Cheng, Yanfei Liu, Qiwen Chen, Yunqi Man, Yunqi Man, Zhirou Zhang, Shuqing Du, Zexiang Lv, Qian Wang, Kan Shao et al. · 2025 · Advanced Drug Delivery Reviews
17. Characteristics of the Cytotoxicity of Taraxacum mongolicum and Taraxacum formosanum in Human Breast Cancer Cells
    Chien-Jung Lin, Jen-Tuo Chen, Lin-Jhen Yeh, Rong-Chi Yang, Shih‐Ming Huang, Teng-Wei Chen · 2022 · International Journal of Molecular Sciences
18. Exploiting the intrinsic misfolding propensity of the KRAS oncoprotein
    Janssen, Kobe, Claes, Filip, Van de Velde, Dido, Wehbi, Vanessa L., Houben, Bert, Lampi, Yulia, Nys, Mieke, Khodaparast, Laleh, Khodaparast, Ladan, Louros, Nikolaos et al. · 2023 · Proceedings of the National Academy of Sciences
19. MicroRNA-708 emerges as a potential candidate to target undruggable NRAS
    Jia Meng Pang, Po-Chen Chien, Ming-Chien Kao, Pei-Yun Chiu, Pin-Xu Chen, Yu-Ling Hsu, Chengyang Liu, Xiaowei Liang, Kai‐Ti Lin · 2023 · PLoS ONE
20. Drug combinations identified by high-throughput screening promote cell cycle transition and upregulate Smad pathways in myeloma
    Tyler J. Peat, Snehal M. Gaikwad, Wendy Dubois, Nana Gyabaah-Kessie, Shuling Zhang, Sayeh Gorjifard, Zaw Hlyan Phyo, Megan Andres, V. Keith Hughitt, Richard J. Simpson et al. · 2023 · Cancer Letters
21. Identification of Potential Inhibitors Targeting GTPase-Kirsten RAt Sarcoma Virus (K-Ras) Driven Cancers via E-Pharmacophore-Based Virtual Screening and Drug Repurposing Approach
    S. Udhaya Kumar, Rinku Polachirakkal Varghese, V. Anu Preethi, C. George Priya Doss, Hatem Zayed · 2023 · Frontiers in Bioscience-Landmark
22. Nano-Inspired Technologies for Peptide Delivery
    Obdulia Covarrubias‐Zambrano, Jing Yu, Stefan H. Bossmann · 2019 · Current Protein and Peptide Science
23. Small Molecule 20S Proteasome Enhancer Regulates MYC Protein Stability and Exhibits Antitumor Activity in Multiple Myeloma
    Evert Njomen, Allison S. Vanecek, Theresa A. Lansdell, Ya-Ting Yang, Peter Z. Schall, Christi M. Harris, Matthew P. Bernard, Daniel Isaac, Omar Abed Alkharabsheh, Anas Al-Janadi et al. · 2022 · Biomedicines
24. Revisiting biomolecular NMR spectroscopy for promoting small-molecule drug discovery
    Hiroyuki Hanzawa, Takashi Shimada, Mizuki Takahashi, Hideo Kohka Takahashi · 2020 · Journal of Biomolecular NMR
25. Functionally analyzing the important roles of hepatocyte nuclear factor 3 (FoxA) in tumorigenesis
    Bing Xin Gao, Wei Xie, Xueji Wu, Lei Wang, Jianping Guo · 2020 · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer
26. Physicochemical Principles Driving Small Molecule Binding to RNA
    Timothy E. H. Allen, James L. McDonagh, Malgorzata Broncel, Carson J. Bryant, Danny Incarnato, Anil Vasudevan, Rabia T. Khan · 2024 · bioRxiv (Cold Spring Harbor Laboratory)
27. A MYC-controlled redox switch protects B lymphoma cells from EGR1-dependent apoptosis
    Haidong Yao, Xue Chen, Ting Wang, Muhammad Kashif, Xi Qiao, Elin Tüksammel, Lars‐Gunnar Larsson, Sam Okret, Volkan I. Sayin, Hong Qian et al. · 2023 · Cell Reports
28. Syrosingopine Enhances 20S Proteasome Activity and Degradation of α-Synuclein
    Yusaku Sadahiro, Soichiro Nishimura, Yuki Hitora, Sachiko Tsukamoto · 2023 · Journal of Natural Products
29. Profiling nuclear cysteine ligandability and effects on nuclear localization using proximity labeling-coupled chemoproteomics
    Qianni Peng, Eranthie Weerapana · 2023 · Cell chemical biology
30. Taming Conformational Heterogeneity on Ion Racetrack to Unveil Principles that Drive Membrane Permeation of Cyclosporines
    Miranda N. Limbach, Edward T. Lindberg, Hernando J. Olivos, Lara van Tetering, Carlos Alberto Steren, Jonathan K. Martens, Van A. Ngo, Jos Oomens, Thanh D. Do · 2024 · JACS Au
31. Finding ways into the cytosol: Peptide-mediated approaches for delivering proteins into cells
    Yoshimasa Kawaguchi, Shiroh Futaki · 2024 · Current Opinion in Chemical Biology
32. Emerging opportunities for intact and native protein analysis using chemical proteomics
    Alexis N. Edwards, Ku‐Lung Hsu · 2024 · Analytica Chimica Acta
33. Inverted chimeric RNAi molecules synergistically cotarget MYC and KRAS in KRAS-driven cancers
    Yogitha S. Chareddy, Hayden P. Huggins, Snehasudha S Sahoo, Lyla J. Stanland, Christina Gutierrez-Ford, Kristina Marinak Whately, Lincy Edatt, Salma H. Azam, Matthew C. Fleming, Jonah Im et al. · 2025 · Journal of Clinical Investigation
34. MedChemLens: An Interactive Visual Tool to Support Direction Selection in Interdisciplinary Experimental Research of Medicinal Chemistry
    Chuhan Shi, Fei Nie, Yicheng Hu, Yige Xu, Lei Chen, Xiaojuan Ma, Qiong Luo · 2022 · IEEE Transactions on Visualization and Computer Graphics
35. Discovery of small molecule β-catenin suppressors that enhance immunotherapy
    Xuchen Feng, Jun Ge, Hui Fu, Lin Miao, Feng Hua Zhao, Jingyu Wang, Yujiao Sun, Yingpeng Li, Yunfei Li · 2023 · Bioorganic Chemistry
36. Médecine de précision et médecine des systèmes: La médecine personnalisée se trompet-elle de cible ?
    Marie Darrason · 2017 · Lato Sensu Revue de la Société de philosophie des sciences
37. Combined computational and intracellular peptide library screening: towards a potent and selective Fra1 inhibitor
    Miao Yu, Lila Ghamsari, Jimmy A. Rotolo, Barry J. Kappel, Jody M. Mason · 2021 · RSC Chemical Biology
38. Prediction and analysis of functional RNA structures within the integrative genomics viewer
    Warren B. Rouse, Ryan J. Andrews, Nicholas J Booher, Jibo Wang, Michael E. Woodman, Ernst R. Dow, Theodore C. Jessop, Walter N. Moss · 2022 · NAR Genomics and Bioinformatics
39. Role of the Ribonuclease ONCONASE in miRNA Biogenesis and tRNA Processing: Focus on Cancer and Viral Infections
    Marta Menegazzi, Giovanni Gotte · 2022 · International Journal of Molecular Sciences
40. Design and assembly of a nanoparticle, antibody, phthalocyanine scaffold for intracellular delivery of photosensitizer to human papillomavirus-transformed cancer cells
    Elvin Peter Chizenga, Heidi Abrahamse · 2023 · Artificial Cells Nanomedicine and Biotechnology
41. MYC protein is a high-risk factor in mantle cell lymphoma and identifies cases beyond morphology, proliferation and TP53/p53 – a Nordic Lymphoma Group study
    Joana M. Rodrigues, Peter Hollander, Lina Schmidt, Eirinaios Gkika, Masoud Razmara, Darshan Kumar, Christian H. Geisler, Kirsten Grønbæk, Christian Winther Eskelund, Riikka Räty et al. · 2023 · Haematologica
42. A chemical approach for the synthesis of the DNA-binding domain of the oncoprotein MYC
    Renata Calo-Lapido, Cristina Penas, Adrián Jiménez‐Balsa, M. Eugenio Vázquez, Jose Luis Mascarenas · 2019 · Organic & Biomolecular Chemistry
43. Harnessing off-target effects
    Gaye Saginc, Franziska Völlmy, Rune Linding · 2017 · Nature Chemical Biology
44. Photoswitchable Cytotoxins
    Oliver Thorn‐Seshold · 2022 · Wiley eBooks
45. MicroRNAs in Hepatocellular Carcinoma: Insights into Regulatory Mechanisms, Clinical Significance, and Therapeutic Potential
    Fenfen Guo, Hong Li, Jingjing Wang, Jiangfeng Wang, Jinling Zhang, Fanfang Kong, Zemin Zhang, Jinbao Zong · 2024 · Cancer Management and Research
46. Aurora A Kinase Inhibition Is Synthetic Lethal With the Activation of MYCN in Retinoblastoma
    Qili Liao, Jie Yang, Hanhan Shi, Reyizha Mengjiang, Yongyun Li, Qianqian Zhang, Xuyang Wen, Shengfang Ge, Peiwei Chai, Xianqun Fan et al. · 2025 · Investigative Ophthalmology & Visual Science
47. Development of MDM2‐Targeting PROTAC for Advancing Bone Regeneration
    Sol Jeong, Jae‐Kook Cha, Wasim Ahmed, Jaewan Kim, Minsup Kim, Kyung Tae Hong, Wonji Choi, Sunjoo Choi, Tae Hyeon Yoo, Hyun‐Ju An et al. · 2025 · Advanced Science
48. Targeting the HER2-ELF3-KRAS axis: a novel therapeutic strategy for KRASG13D colorectal cancer
    Soo‐Yeon Hwang, Yoojeong Seo, Seojeong Park, Seul-Ah Kim, Inhye Moon, Yi Liu, Seojeong Kim, Eun Seon Pak, Sehyun Jung, Hyeyoon Kim et al. · 2025 · Molecular Cancer
49. Nano-TPD: Using nanoparticle-based systems to improve the delivery and therapeutic effect of targeted protein degraders
    Kuntala Dey, Nina Erwin, Nicolas Molina, Hui Chen, Mei He, Guangrong Zheng · 2025 · Medicinal Chemistry Research
50. Discovery of a Novel Series of iso -Indolinone-Based Glutarimides as Highly Efficacious and Selective IKZF2 Molecular Glue Degraders
    Xuqing Zhang, Harshil Dhruv, Qiaolin Deng, Matthew Tudor, Nelisa Bechtel, Rakesh Nagilla, Larry J. Jolivette, Cory Rice, Peter Orth, Elham Behshad et al. · 2025 · Journal of Medicinal Chemistry
51. KRAS-targeted therapies in cancer: novel approaches and overcoming resistance
    Daolin Tang, Guido Kroemer, Rui Kang · 2025 · BMJ Oncology
52. Current Approaches for Personalized Therapy of Soft Tissue Sarcomas
    Кирсанов Кирилл Игоревич, Ekaterina A. Lesovaya, Timur I. Fetisov, Beniamin Yu. Bokhyan, Gennady A. Belitsky, Якубовская Марианна Геннадиевна · 2020 · Sarcoma
53. Miz1 promotes KRAS-driven lung tumorigenesis by repressing the protocadherin Pcdh10
    Jing Yang, Changchun Hou, Huashan Wang, Edith A. Perez, Hanh Chi Do-Umehara, Huali Dong, Vinothini Arunagiri, Fangjia Tong, Michelle M. Van Scoyk, Minsu Cho et al. · 2022 · Cancer Letters
54. Facts and Hopes in Using Omics to Advance Combined Immunotherapy Strategies
    Ryan C. Augustin, Wesley L. Cai, Jason J. Luke, Riyue Bao · 2024 · Clinical Cancer Research
55. Synthesis, SAR, and application of JQ1 analogs as PROTACs for cancer therapy
    Soumik De, Raghaba Sahu, Shubhendu Palei, Laxmi Narayan Nanda · 2024 · Bioorganic & Medicinal Chemistry
56. Global Profiling Lysine Reactivity and Ligandability with Oxidant‐Triggered Bioconjugation Chemistry
    Mengya Zhou, Shengrong Li, Yi Tan, Weizhen Huang, Yi-Fang Li, Xia Yuan, Zhengqiu Li · 2024 · Angewandte Chemie International Edition
57. Non-coding RNAs as key regulators in hepatitis B virus-related hepatocellular carcinoma
    Prasanna Srinivasan Ramalingam, Liming Zhang, Md Sadique Hussain, Gyas Khan, Wedad Mawkili, Ali Hanbashi, Gaurav Gupta, Purushothaman Balakrishnan, Sivakumar Arumugam · 2025 · Frontiers in Immunology
58. Artificial intelligence, molecular subtyping, biomarkers, and precision oncology
    John Paul Shen · 2021 · Emerging Topics in Life Sciences
59. The emerging role of noncoding RNAs in the Hedgehog signaling pathway in cancer
    Xue Han, Bo Li · 2022 · Biomedicine & Pharmacotherapy
60. Isoform-specific knockdown of long and intermediate prolactin receptors interferes with evolution of B-cell neoplasms
    Adeleh Taghi Khani, Anil Kumar, Ashly Sanchez Ortiz, Kelly C. Radecki, Soraya Aramburo, Sung June Lee, Zunsong Hu, Behzad Damirchi, Mary Y. Lorenson, Xiwei Wu et al. · 2023 · Communications Biology
61. A modified gene trap approach for improved high-throughput cancer drug discovery
    Shelli M. Morris, Andrew J. Mhyre, Savanna S. Carmack, Carrie H. Myers, Connor Burns, Wenjuan Ye, Marc Ferrer, James M. Olson, Richard A. Klinghoffer · 2018 · Oncogene
62. KRAS G12C Inhibitors on the Horizon
    Ali Çağır, Asfar Sohail Azmi · 2019 · Future Medicinal Chemistry
63. Targeting and extending the eukaryotic druggable genome with natural products
    Hendrik Luesch, John B. MacMillan · 2020 · Natural Product Reports
64. The Diarylheptanoid Curcumin Induces MYC Inhibition and Cross-Links This Oncoprotein to the Coactivator TRRAP
    Mödlhammer, Alexander, Pfurtscheller, Sandra, Feichtner, Andreas, Hartl, Markus, Schneider, Rainer · 2021 · Frontiers in Oncology
65. A Structure-Based Allosteric Modulator Design Paradigm
    Mingyu Li, Xiaobin Lan, Xun Lu, Jian Zhang · 2023 · Health Data Science
66. The MYC-Regulated RNA-Binding Proteins hnRNPC and LARP1 Are Drivers of Multiple Myeloma Cell Growth and Disease Progression and Negatively Predict Patient Survival
    Marcel Seibert, Sebastian E. Koschade, Verena Stolp, Björn Häupl, Frank Wempe, Hubert L. Serve, Nina Kurrle, Frank Schnütgen, Ivana von Metzler · 2023 · Cancers
67. IKZF2 Degradation: It′s Time to Take into Account it When Designing Cereblon‐Based PROTACs
    Minglei Li · 2024 · ChemBioChem
68. Therapeutic peptides targeting intracellular molecules
    Rahela Zaman, Ezharul Hoque Chowdhury · 2024 · European Polymer Journal
69. CIGB-300 internalizes and impairs viability of NSCLC cells lacking actionable targets by inhibiting casein kinase-2 signaling
    Ying Yi, Lingfeng Dai, Yaqin Lan, Changyuan Tan, Dania Vázquez‐Blomquist, Guirong Zeng, Dejian Jiang, Ke Yang, Silvio E. Perea, Yasser Perera · 2024 · Scientific Reports
70. Dioxazolones as Masked Isocyanate Electrophiles for Global Profiling of Lysine Reactivity and Ligandability
    Yanxia Feng, Shihan Zeng, Fang Xu, Weizhen Huang, Shengrong Li, Yi Tan, Zhengqiu Li · 2025 · Journal of the American Chemical Society
71. Transcriptional regulators of human oncoviruses: structural and functional implications for anticancer therapy
    Ivona Nečasová, Martin Stojaspal, Edita Motyčáková, Tomáš Brom, Tomáš Janovič, Ctirad Hofr · 2022 · NAR Cancer
72. Advances in RNA therapeutics for modulation of ‘undruggable’ targets
    Emily Martinsen, Tasmia Jinnurine, Saranya Subramani, Marie Rogne · 2024 · Progress in molecular biology and translational science
73. Inflammasome-Inhibiting Nanoligomers Are Neuroprotective against Space-Induced Pathology in Healthy and Diseased Three-Dimensional Human Motor and Prefrontal Cortex Brain Organoids
    Sadhana Sharma, Vincenzo S. Gilberto, Jon C. Rask, Anushree Chatterjee, Prashant Nagpal · 2024 · ACS Chemical Neuroscience
74. Synergistic anti-tumor activity, reduced pERK, and immuno-stimulatory cytokine profiles with 5-FU or ONC212 plus KRAS G12D inhibitor MRTX1133 in CRC and pancreatic cancer cells independent of G12D mutation
    Vida Tajiknia, Maximilian P. Pinho-Schwermann, Praveen R. Srinivasan, Liz J. Hernández Borrero, Leiqing Zhang, Kelsey E. Huntington, Wafik S. El‐Deiry · 2024 · American Journal of Cancer Research
75. Attractor Landscape Analysis Reveals a Reversion Switch in the Transition of Colorectal Tumorigenesis
    Dongkwan Shin, Jeong‐Ryeol Gong, Sang Kwon Jeong, Young-Won Cho, Hwang‐Phill Kim, Tae‐You Kim, Kwang‐Hyun Cho · 2025 · Advanced Science
76. Structural insights into human brachyury DNA recognition and discovery of progressible binders for cancer therapy
    Joseph A. Newman, Angeline E. Gavard, Nergis Imprachim, H. Aitkenhead, Hadley E. Sheppard, Robert te Poele, Paul Andrew Clarke, Mohammad Anwar Hossain, Louisa Temme, Hans J. Oh et al. · 2025 · Nature Communications
77. Beute für das Proteasom: Gezielter Proteinabbau aus medizinalchemischer Perspektive
    Laura Martina Luh, Ulrike Scheib, Katrin Juenemann, Lars Wortmann, Michael Brands, Philipp M. Cromm · 2020 · Angewandte Chemie
78. A high-content screen identifies the vulnerability of MYC-overexpressing cells to dimethylfasudil
    Jing Zhang, Shenqiu Zhang, Qiong Shi, Thaddeus D. Allen, Fengming You, Dun Yang · 2021 · PLoS ONE
79. Zwint facilitates melanoma progression by promoting c‑Myc expression
    Kuanhou Mou, Jian Zhang, Xin Ni Mu, Lijuan Wang, Wenli Liu, Rui Ge · 2021 · Experimental and Therapeutic Medicine
80. Roles of Key Epigenetic Regulators in the Gene Transcription and Progression of Prostate Cancer
    Tanggang Deng, Yugang Xiao, Yi Dai, Lin Ying Xie, Xiong Li · 2021 · Frontiers in Molecular Biosciences
81. Developing PROteolysis TArgeting Chimeras (PROTACs) for hematologic malignancies
    Yangping Wu, Jingliao Zhang, Xiaofan Zhu, Yingchi Zhang · 2022 · Cancer Letters
82. Capsule-based automated synthesis for the efficient assembly of PROTAC like molecules
    Samuele Bordi, Tuo Jiang, Anna Konopka, Guillaume Coin, Paula L. Nichols, Benedikt M. Wanner · 2023 · Digital Discovery
83. The TATA‐binding Protein DNA‐binding domain of eukaryotic parasites is a potentially druggable target
    Ángel Santiago, Rodrigo Said Razo‐Hernández, Nina Pastor · 2019 · Chemical Biology & Drug Design
84. Photoregulation of Gene Expression with Amantadine‐Modified Caged siRNAs through Host–Guest Interactions
    Jinhao Zhang, Nannan Jing, Xinli Fan, Xinjing Tang · 2020 · Chemistry - A European Journal
85. Molecular Glue Degraders: From Serendipity to Hunting and Design
    Luis Nieto‐Barrado, Ana Domostegui, Cristina Mayor‐Ruiz · 2022 · Wiley eBooks
86. Brachyury expression is highly specific for chordoma: A tissue microarray study involving 14,976 cancers from 135 different tumor types and subtypes
    Piero Caneve, Nina Schraps, Katharina Möller, Şeyma Büyücek, Florian Lutz, Viktoria Chirico, Florian Viehweger, Viktor Reiswich, Clara Marie von Bargen, Simon Kind et al. · 2025 · Annals of Diagnostic Pathology
87. Biased Equilibrium Drives Cyclosporine Membrane Permeability: The Goldilocks Energy Barriers
    Miranda N. Limbach, Edward T. Lindberg, Chetana Shrestha, Jinchao Lou, Carlos Alberto Steren, Michael D. Best, Thanh D. Do · 2025 · Journal of Medicinal Chemistry
88. Benzofuranyl-pyrazole as a Novel Scaffold for In Vitro and In Vivo Potent Anticancer Therapeutics That Directly Disrupt the ‘Undruggable’ MYC Oncogene and Potentiate Immune Checkpoint Blockage
    Liuqing Yang, Haojie Zuo, Mengdie Sha, Wenhu Zhan, Jiaming Li, Yulei Liu, Fang Fang, Yang Wang, Xiaodong Ma · 2025 · Journal of Medicinal Chemistry
89. Context-dependent translation inhibition as a cancer therapeutic modality
    Paige D. Diamond, Paul Victor Sauer, Mikael Holm, Canessa J. Swanson-Swett, Lucas Ferguson, Natalie M. Bratset, Grant W. Wienker, Justin Seiwert Sim, Hailey Adams, Lillian R. Kenner et al. · 2026 · Nature Communications
90. Ribosome stalling during c-myc translation presents actionable cancer cell vulnerability
    Tejinder Pal Khaket, Suman Rimal, Xingjun Wang, Sunil Bhurtel, Yen-Chi Wu, Bingwei Lu · 2024 · PNAS Nexus
91. Discovery of Bi-magnolignan as a novel BRD4 inhibitor inducing apoptosis and DNA damage for cancer therapy
    Zifeng Huang, Tong Chu, Ai‐Jun Ma, Wanjun Lin, Yan Gao, Na Zhang, Meina Shi, Xuening Zhang, Yanchao Yang, Wenzhe Ma · 2025 · Biochemical Pharmacology
92. Clearance prediction for Amgen molecules against Extended Clearance Classification System (ECCS) and future directions
    Prashant Agarwal, Kazuya Ishida, Darren L. Reid, Anshul Gupta · 2020 · Drug Discovery Today
93. Ligandability Assessment of Human Glutathione Transferase M1-1 Using Pesticides as Chemical Probes
    Charoutioun S. Bodourian, Nirmal Poudel, Anastassios C. Papageorgiou, Mariana Antoniadi, Nikolaos Georgakis, Hiroshi Abe, Nikolaos E. Labrou · 2022 · International Journal of Molecular Sciences
94. Deregulation of PRDM5 promotes cell proliferation by regulating JAK / STAT signaling pathway through SOCS1 in human lung adenocarcinoma
    Yuanyuan Ren, Ye Wang, Lijiao Fang, Mengchu Ma, Lin Ge, Chao Su, Lingbiao Xin, Jinyan He, Jie Yang, Xin Liu · 2022 · Cancer Medicine
95. Inhibition of high level E2F in a RB1 proficient MYCN overexpressing chicken retinoblastoma model normalizes neoplastic behaviour
    Hanzhao Zhang, Dardan Konjusha, Nima Rafati, Tatsiana Tararuk, Finn Hallböök · 2023 · Cellular Oncology
96. Mitogen-activated protein kinase-guided drug discovery for post-viral and related types of lung disease
    Michael J. Holtzman, Yong Zhang, Kangyun Wu, Arthur G. Romero · 2024 · European Respiratory Review
97. Cancer and insulin-like growth factor inhibitors: Recent advancements and SAR analysis
    Diksha Choudhary, Bhupinder Kumar, Amandeep Thakur · 2024 · Elsevier eBooks
98. Introduction to drug discovery
    Stephanie Kay Ashenden · 2021 · Elsevier eBooks
99. SuperDendrix algorithm integrates genetic dependencies and genomic alterations across pathways and cancer types
    Tae Yoon Park, Mark D.M. Leiserson, Gunnar W. Klau, Benjamin J. Raphael · 2022 · Cell Genomics
100. Oncogenes in high grade serous adenocarcinoma of the ovary
     Pacharla Manasa, Chirukandath Sidhanth, S Krishnapriya, Sekar Vasudevan, Trivadi Sundaram Ganesan · 2020 · Genes & Cancer